SLE is a disease with autoimmune disturbance and inflammatory damage, so blocking TNF-α in this autoimmune-prone chronic inflammatory disease may lead to different outcomes, depending on timing and duration of treatment[18]. This evidence concerns the gene TNF and systemic lupus erythematosus.